Your browser doesn't support javascript.
loading
A new prognostic score for predicting survival in patients treated with robotic stereotactic radiotherapy for brain metastases.
Stankiewicz, Magdalena; Tomasik, Bartlomiej; Blamek, Slawomir.
Affiliation
  • Stankiewicz M; Brachytherapy Department, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland. magdalena.stankiewicz@io.gliwice.pl.
  • Tomasik B; Radiotherapy Department, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland.
  • Blamek S; Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland.
Sci Rep ; 11(1): 20347, 2021 10 13.
Article in En | MEDLINE | ID: mdl-34645854
ABSTRACT
The study aimed to analyze potential prognostic factors in patients treated with robotic radiosurgery for brain metastases irrespective of primary tumor location and create a simple prognostic score that can be used without a full diagnostic workup. A retrospective analysis of 142 patients with 1-9 brain metastases treated with stereotactic radiosurgery (1-4 fractions) was performed. Volumes of all lesions were calculated using linear dimensions of the tumors (CC, LR, AP) and 4/3*π*(CC/2)*(LR/2)*(AP/2) formula. Kaplan-Meier method and log-rank test were used to analyze survival. Variables significantly associated with overall survival in univariate analysis were included in Cox multivariate analysis. The validity of the model was tested with the bootstrap method. Variables from the final model were used to construct a new prognostic index by assigning points according to the impact of a specific variable on overall survival. In the multivariate analysis, four factors Karnofsky Performance Status (p = 0.000068), number of brain metastases (p = 0.019), volume of the largest lesion (p = 0.0037), and presence of extracerebral metastases (p = 0.0017), were independent predictors of survival. Total scores ranged from 0 to 12 points, and patients were divided into four groups based on median survival of each subgroup 0-1 points-18.8 months, 2-3 points-16.9 months, 4-5 points-5.6 months, and ≥ 6 points-4.9 months (p < 0.001). The new prognostic index is simple to calculate. It has a strong prognostic value in a heterogeneous population of patients with a various number of brain metastases, but its value requires confirmation in another cohort.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Robotics / Brain Neoplasms / Radiosurgery Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Sci Rep Year: 2021 Document type: Article Affiliation country: Polonia

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Robotics / Brain Neoplasms / Radiosurgery Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Sci Rep Year: 2021 Document type: Article Affiliation country: Polonia